Management Report

6. Calculation of EBIT(DA) Before Special Items

Key performance indicators for the Bayer Group are ebit before special items and ebitda before special items. These indicators are reported in order to allow a more accurate assessment of business operations. The special items – comprising effects that are non-recurring or do not regularly recur or attain similar magnitudes – are detailed in the following table. ebitda, ebitda before special items and ebit before special items are not defined in the International Financial Reporting Standards (IFRS) and should therefore be regarded only as supplementary information. ebitda before special items is a meaningful indicator of operating performance since it is not affected by depreciation, amortization, impairment losses, impairment loss reversals or special items. By reporting this indicator, the company aims to give readers a clear picture of the results of operations and to ensure comparability of data over time. The ebitda margin before special items, which is the ratio of ebitda before special items to sales, serves as a relative indicator for the internal and external comparison of operational earning power.

Depreciation, amortization and impairments rose by 20.1% in the first half of 2015 to €1,616 million (h1 2014: €1,345 million), comprising €870 million (h1 2014: €711) in amortization and impairments of intangible assets and €746 million (h1 2014: €634 million) in depreciation and impairments of property, plant and equipment.  Impairments totaled €67 million (h1 2014: €49 million), of which €52 million (h1 2014: €7 million) was included in special items.

Special Items Reconciliation      [Table 13]
  EBIT1
2nd
Quarter
2014
EBIT1
2nd
Quarter
2015
EBIT1
1st
Half
2014
EBIT1
1st
Half
2015
EBITDA2
2nd
Quarter
2014
EBITDA2
2nd
Quarter
2015
EBITDA2
1st
Half
2014
EBITDA2
1st
Half
2015
  € million € million € million € million € million € million € million € million
Before special items 1,483 2,088 3,541 4,276 2,176 2,899 4,879 5,840
HealthCare (25) (145) (9) (290) (21) (142) (5) (265)
Restructuring (32) - (73) (29) (48)
Litigations (1) - (14) (1) (14)
Integration costs (25) (55) (44) (146) (21) (55) (40) (146)
Settlement of pre-existing relationship 35 35
Divestitures 3 3 3 3
Revaluation of other receivables (60) (60) (60) (60)
CropScience (28) (75) (28) (70)
Litigations (17) (18) (17) (18)
Divestitures (46) (41)
Revaluation of other receivables (11) (11) (11) (11)
MaterialScience (17) (59) (19) (101) (14) (58) (16) (79)
Restructuring (17) (57) (19) (99) (14) (56) (16) (77)
Revaluation of other receivables (2) (2) (2) (2)
Reconciliation (6) (23) (13) (33) (6) (23) (13) (33)
Restructuring (6) (22) (13) (32) (6) (22) (13) (32)
Revaluation of other receivables (1) (1) (1) (1)
Total special items (48) (255) (41) (499) (41) (251) (34) (447)
of which cost of goods sold (10) (51) (10) (237) (10) (48) (10) (191)
of which selling expenses (7) (45) (11) (71) (7) (46) (11) (67)
of which research and development expenses (2) (9) (2) (11) (2) (7) (2) (9)
of which general administration expenses (17) (43) (27) (63) (13) (43) (23) (63)
of which other operating income/expenses (12) (107) 9 (117) (9) (107) 12 (117)
After special items 1,435 1,833 3,500 3,777 2,135 2,648 4,845 5,393
2014 figures restated
1 EBIT = earnings before financial result and taxes
2 EBITDA = EBIT plus amortization and impairment losses on intangible assets, plus depreciation and impairment losses on property, plant and equipment, minus impairment loss reversals
Last updated: July 29, 2015  Copyright © Bayer AG
http://www.quarterly-report-2015-q2.bayer.com